Xspray Pharma AB (publ)

Stockholm Stock Exchange XSPRAY.ST

Xspray Pharma AB (publ) Shareholders' Equity for the year ending December 31, 2023: USD 68.44 M

Xspray Pharma AB (publ) Shareholders' Equity is USD 68.44 M for the year ending December 31, 2023, a 28.89% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Xspray Pharma AB (publ) Shareholders' Equity for the year ending December 31, 2022 was USD 53.10 M, a -18.50% change year over year.
Xspray Pharma AB (publ) Shareholders' Equity for the year ending December 31, 2021 was USD 65.15 M, a -7.73% change year over year.
Xspray Pharma AB (publ) Shareholders' Equity for the year ending December 31, 2020 was USD 70.61 M, a 77.57% change year over year.
Xspray Pharma AB (publ) Shareholders' Equity for the year ending December 31, 2019 was USD 39.76 M, a 17.15% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Stockholm Stock Exchange: XSPRAY.ST

Xspray Pharma AB (publ)

CEO	Dr. Per Andersson Ph.D.
IPO Date	Sept. 28, 2017
Location	Sweden
Headquarters	Råsundavägen 12
Employees	24
Sector	Healthcare
Industries Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Non-Alcoholic Beverages Pharmaceuticals

Description

Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.

Key trends

Past 5 years